Steven Lehrer1, Peter H Rheinstein2, Kenneth E Rosenzweig2. 1. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A. steven.lehrer@mssm.edu. 2. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.
Abstract
BACKGROUND/AIM: Glioblastoma multiforme (GBM) is the most common primary tumor of the central nervous system. The serum and glucocorticoid-regulated kinase SGK1 gene is required for the growth and survival of GBM stem-like cells under both normoxic and hypoxic conditions. It has been reported that oxygenation significantly affects cellular genetic expression; 30% of the genes required in hypoxia were not required under normoxic conditions. Therefore, we examined SGK1 expression to determine if it may be a novel potential drug target for GBM. MATERIALS AND METHODS: We assessed the association between SGK1 and glioblastoma patient overall survival using the GBM cohort in TCGA (The Cancer Genome Atlas) database (TCGA-GBM). To access and analyze the data we used the UCSC Xena browser (https://xenabrowser.net). Survival data of the GBM subgroup were extracted for analysis and generation of Kaplan-Meier curves for overall survival. The best cut-off was identified by methods described in the R2 web-based application (http://r2.amc.nl). RESULTS: We analyzed patient survival by tumor SGK1 copy number segments after removal of common germ-line copy-number variants (CNVs). Copy number segments (log2 tumor/normal) ≤0.009700 were associated with significantly poorer survival (p=0.016). CONCLUSION: Increased median overall survival associated with increased SGK1 copy number segments may be a reflection of better tumor oxygenation. Therefore, besides being a drug target, SGK1 may also be a prognostic marker. Among molecular tumor markers, only the methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) gene has shown a significant association with survival in patients with GBM. Copyright
BACKGROUND/AIM: Glioblastoma multiforme (GBM) is the most common primary tumor of the central nervous system. The serum and glucocorticoid-regulated kinase SGK1 gene is required for the growth and survival of GBM stem-like cells under both normoxic and hypoxic conditions. It has been reported that oxygenation significantly affects cellular genetic expression; 30% of the genes required in hypoxia were not required under normoxic conditions. Therefore, we examined SGK1 expression to determine if it may be a novel potential drug target for GBM. MATERIALS AND METHODS: We assessed the association between SGK1 and glioblastomapatient overall survival using the GBM cohort in TCGA (The Cancer Genome Atlas) database (TCGA-GBM). To access and analyze the data we used the UCSC Xena browser (https://xenabrowser.net). Survival data of the GBM subgroup were extracted for analysis and generation of Kaplan-Meier curves for overall survival. The best cut-off was identified by methods described in the R2 web-based application (http://r2.amc.nl). RESULTS: We analyzed patient survival by tumorSGK1 copy number segments after removal of common germ-line copy-number variants (CNVs). Copy number segments (log2 tumor/normal) ≤0.009700 were associated with significantly poorer survival (p=0.016). CONCLUSION: Increased median overall survival associated with increased SGK1 copy number segments may be a reflection of better tumor oxygenation. Therefore, besides being a drug target, SGK1 may also be a prognostic marker. Among molecular tumor markers, only the methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) gene has shown a significant association with survival in patients with GBM. Copyright
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Anton G Moll; Maja T Lindenmeyer; Matthias Kretzler; Peter J Nelson; Ralf Zimmer; Clemens D Cohen Journal: PLoS One Date: 2009-03-11 Impact factor: 3.240
Authors: YuFeng Xiong; MingRui Pang; Yang Du; Xi Yu; JingPing Yuan; Wen Liu; Lei Wang; XiuHeng Liu Journal: Front Oncol Date: 2022-05-12 Impact factor: 5.738
Authors: Konrad Aden; Kareen Bartsch; Joseph Dahl; Martin A M Reijns; Daniela Esser; Raheleh Sheibani-Tezerji; Anupam Sinha; Felix Wottawa; Go Ito; Neha Mishra; Katharina Knittler; Adam Burkholder; Lina Welz; Johan van Es; Florian Tran; Simone Lipinski; Nassim Kakavand; Christine Boeger; Ralph Lucius; Witigo von Schoenfels; Clemens Schafmayer; Lennart Lenk; Athena Chalaris; Hans Clevers; Christoph Röcken; Christoph Kaleta; Stefan Rose-John; Stefan Schreiber; Thomas Kunkel; Björn Rabe; Philip Rosenstiel Journal: Gastroenterology Date: 2018-09-28 Impact factor: 22.682
Authors: Zachary S Buchwald; Sibo Tian; Michael Rossi; Geoffrey H Smith; Jeffrey Switchenko; Jennifer E Hauenstein; Carlos S Moreno; Robert H Press; Roshan S Prabhu; Jim Zhong; Debra F Saxe; Stewart G Neill; Jeffrey J Olson; Ian R Crocker; Walter J Curran; Hui-Kuo G Shu Journal: Sci Rep Date: 2020-04-30 Impact factor: 4.379